AstraZeneca Results Presentation Deck
Lynparza
The globally-leading PARP¹ inhibitor
$m
12
700
600
500
400
300
200
100
Q1 2018
Q2 2018
Q3 2018
34% growth in
sales to $1.1bn
Q4 2018
Q1 2019
CO2 2019
Q3 2019
%Q4 2019
Product sales at actual exchange rates; changes
at CER and for H1 2021, unless stated otherwise.
1. Poly ADP ribose polymerase.
Q1 2020
Q2 2020
Lynnarza
Q3 2020
Q4 2020
Q1 2021
Q2 2021
As
●
Approvals 84 (ovarian), 82 (breast), 63
(pancreatic) and 60 (prostate cancer)
AstraZeneca
US +29% (46% of total)
Growth primarily driven
by use in prostate cancer
Europe +38%
Growth in 1st-line OC²
and in prostate cancer
EM +50%
Expanded China NRDL supported OC
EROW +26%
Japan: +20%; c.14% Q2 2020 price cut
2. Ovarian cancer.
Ĵ
Q3 2017
Q4 2017
Q1 2018
Upfront payment
Q2 2018
Collaboration
revenue
Q3 2018
Q4 2018
Option
Q1 2019
payments
Q2 2019
Q3 2019
Q4
2019
Q1 2020
Regulatory
Q2 2020
Q3 2020
Q4 2020
Q1 2021
Q2 2021
$m
Collaboration revenue at actual exchange rates.
Collaboration with Merck & Co., Inc., Kenilworth, NJ, US, known as MSD out-
side the US and Canada. $3.1bn revenue recorded; $4.6bn future potential.
1,000
800
600
400
200
0
milestones Sales milestones
B
THE
TRE
FOR PView entire presentation